Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Travere Therapeutics Inc shares valued at $37,553 were sold by Cline Christopher R. on May 05 ’25. At $21.05 per share, Cline Christopher R. sold 1,784 shares. The insider’s holdings dropped to 93,126 shares worth approximately $1.34 million following the completion of this transaction.
Also, Dube Eric M sold 18,924 shares, netting a total of over 398,350 in proceeds. Following the sale of shares at $21.05 each, the insider now holds 419,173 shares.
Before that, Heerma Peter had sold 1,771 shares from its account. In a trade valued at $37,280, the CHIEF COMMERCIAL OFFICER traded Travere Therapeutics Inc shares for $21.05 each. Upon closing the transaction, the insider’s holdings decreased to 1,771 shares, worth approximately $1.85 million.
Analysts at Citigroup resumed the stock at ‘”a Buy”‘ outlook in a report released in mid June. As of January 10, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for TVTX. Earlier on October 21, 2024, Wells Fargo upgraded its rating. Their new recommendation was “an Overweight” for TVTX stock which previously was a “an Equal weight”.
Analyzing TVTX Stock Performance
On last trading session,, Travere Therapeutics Inc [NASDAQ: TVTX] rose 2.31% to $14.41. During the last five days, there has been a drop of approximately -0.76%. Over the course of the year, Travere Therapeutics Inc shares have dropped approximately -17.28%. Shares of the company reached a 52-week high of $25.29 on 02/11/25 and a 52-week low of $12.91 on 04/09/25.
Support And Resistance Levels for Travere Therapeutics Inc (TVTX)
According to the 24-hour chart, there is a support level at 14.02, which, if violated, would cause prices to drop to 13.64. In the upper region, resistance lies at 14.65. The next price resistance is at 14.89. RSI (Relative Strength Index) is 39.06 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Travere Therapeutics Inc (TVTX)?
In terms of Travere Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 21.5 in the next 12 months, up nearly 52.59% from the previous closing price of $14.09. Analysts anticipate Travere Therapeutics Inc stock to reach 33 by 2025, with the lowest price target being 12. In spite of this, 8 analysts ranked Travere Therapeutics Inc stock as Buy at the end of 2025.
